Bendamustine (hydrochloride)

• UNSPSC Description:

  Bendamustine hydrochloride (SDX-105), a purine analogue, is a DNA cross-linking agent. Bendamustine hydrochloride activats DNA-damage stress response and apoptosis. Bendamustine hydrochloride has potent alkylating, anticancer and antimetabolite properties[1].

• Target Antigen:

  Apoptosis; DNA Alkylator/Crosslinker

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bendamustine-hydrochloride.html

• Purity:

  99.89

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|H2O : 10 mg/mL (ultrasonic)

• Smiles:

  CN1C(C=CC(N(CCCl)CCCl)=C2)=C2N=C1CCCC(O)=O.Cl

• Molecular Weight:

  394.72378

• References & Citations:

  [1]Leoni LM, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14(1):309-17.|[2]Cives M, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013 May;25(5):1108-17.|[3]Ackler S, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol. 2012 Oct;167(4):881-91.J Biomed Res. 2017 0(0): 1-12.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|Patent. US20160222465A1.|Leukemia. 2023 Sep 26.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  Launched

• CAS Number:

  3543-75-7